💊 Twelve More Months of DAPT, Fewer Heart Attacks, No Extra Bleeding

🫀 Should dual antiplatelet therapy continue beyond 12 months? The DAPT-MVD trial (NEJM 2026) suggests that carefully selected patients with multivessel coronary artery disease who remain event-free after one year of therapy may benefit from another 12 months of clopidogrel plus aspirin. The result? Fewer cardiovascular events—driven largely by fewer myocardial infarctions—without more clinically relevant bleeding in this low-bleeding-risk cohort. ⚖️ A timely reminder that the future of DAPT lies in precision patient selection, not a one-size-fits-all approach. 🩺📚 #Cardiology #DAPT #MedicalEducation #MedicalPodcasts #NEJM